[1]
Bridge Denckla M.: ADHD: topic update. Brain Dev., 2003: 25(6), 383–
389.
[2]
Whalen C.K, Jamner L.D., Henker B. et al.: The ADHD spectrum and
everyday life: experience sampling of adolescent moods, activities,
smoking, and drinking. Child Dev., 2002: 73(1), 209–227.
[3]
Harpin V.A.: The effect of ADHD on the life of an individual, their family,
and community from preschool to adult life. Arch. Dis. Child, 2005: 90
Suppl. 1, 12–17.
[4]
Edbom T., Lichtenstein P., Granlund M. et al.: Long-term relationships
between symptoms of Attention Deficit Hyperactivity Disorder and
self-esteem in a prospective longitudinal study of twins. Acta Paediatr.,
2006: 95(6), 650–657.
[5]
Elkins I.J., McGue M., Iacono W.G.: Prospective effects of attentiondeficit/hyperactivity disorder, conduct disorder, and sex on adolescent
substance use and abuse. Arch. Gen. Psychiatry, 2007: 64(10), 1145–
1152.
[6]
Loe I.M., Feldman H.M.: Academic and educational outcomes of children
with ADHD. J. Pediatr. Psychol., 2007:32(6), 643–654.
[7]
Rodriguez A., Jarvelin M.R., Obel C. et al.: Do inattention and hyperactivity symptoms equal scholastic impairment? Evidence from three European cohorts. BMC Public. Health., 2007: 7(147), 327.
[8]
Hoza B.: Peer functioning in children with ADHD. J. Pediatr. Psychol.,
2007: 32(6), 655–663.
[9]
Sergeant J.A., Geurts H., Huijbregts S., et al.: The top and the bottom
of ADHD: a neuropsychological perspective. Neurosci. Biobehav. Rev.,
2003: 27(7), 583–592.
[10]
Pasini A., Paloscia C., Alessandrelli R. et al.: Attention and executive
functions profile in drug naive ADHD subtypes. Brain Dev. 2007: 29(7),
400–408.
[11]
Castellanos F.X., Sonuga-Barke E.J., Milham M.P. et al.: Characterizing
cognition in ADHD: beyond executive dysfunction. Trends. Cogn. Sci.,
2006: 10(3), 117–123.
[12]
Sonuga-Barke E.J.: Causal models of attention-deficit/hyperactivity
disorder: from common simple deficits to multiple developmental pathways. Biol. Psychiatry, 2005: 57(11), 1231–1238.
[13]
Nigg J.T., Casey B.J.: An integrative theory of attention-deficit/ hyperactivity disorder based on the cognitive and affective neurosciences. Dev.
Psychopathol., 2005: 17(3), 785–806.
[14]
Curatolo P.: The neurology of attention deficit/hyperactivity disorder.
Brain Dev., 2005: 27(8), 541–543.
[15]
Suskauer S.J., Simmonds D.J., Fotedar S. et al.: Functional magnetic
resonance imaging evidence for abnormalities in response selection in
attention deficit hyperactivity disorder: differences in activation associated with response inhibition but not habitual motor response. J Cogn.
Neurosci., 2008: 20(3), 478–493.
[16]
Still G.: The Coulstonian lectures on some abnormal physical conditions in
children. Lecture 1. Lancet, 1902: 1008–1012, 1077–1082, 1163–1168.
[17]
Bond E., Smith L.: Post-encephalitic behavior disorders: a ten-year
review of the Franklin School. Am. J. Psychiatry, 1935: 91, 17–31.
[18]
Bradley C.: The behavior of children receiving Benzedrine. American
Journal of Psychiatry, 1937: 94,577–585.
[19]
Denckla M.B., Rudel R.G.: Anomalies of motor development in hyperactive boys. Ann. Neurol., 1978: 3(3), 231–233.
[20]
American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders. 3rd (DSM-III) ed. Washington: American Psychiatric
Association, 1980.
[21]
American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders. 4th (DSM-IV) ed. Washington: American Psychiatric
Association, 1994.
[22]
Barkley R.A.: Behavioral inhibition, sustained attention, and executive
functions: constructing a unifying theory of ADHD. Psychol. Bull., 1997:
121(1), 65–94.
[23]
Willcutt E.G., Doyle A.E., Nigg J.T. et al.: Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic
review. Biol. Psychiatry, 2005: 57(11), 1336–1346.
[24]
Bush G., Frazier J.A., Rauch S.L. et al. Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the
Counting Stroop. Biol. Psychiatry, 1999: 45(12), 1542–1552.
[25]
Rubia K., Overmeyer S., Taylor E. et al.: Hypofrontality in attention deficit
hyperactivity disorder during higher-order motor control: a study with
functional MRI. Am. J. Psychiatry, 1999: 156(6), 891–896.
[26]
Gilbert D.L., Wang Z., Sallee F.R. et al.: Dopamine transporter genotype
influences the physiological response to medication in ADHD. Brain,
2006: 129(Pt 8), 2038–2046.
[27]
Moll G.H., Heinrich H., Trott G. et al.: Deficient intracortical inhibition in drugnaive children with attention-deficit hyperactivity disorder is enhanced by
methylphenidate. Neurosci. Lett., 2000: 284(1–2), 121–125.
[28]
Buchmann J., Gierow W., Weber S. et al.: Restoration of disturbed intracortical motor inhibition and facilitation in attention deficit hyperactivity disorder children by methylphenidate. Biol. Psychiatry, 2007: 62(9),
963–969.
[29]
Faraone S.V., Doyle A.E.: The nature and heritability of attention-deficit/hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N. Am., 2001:
10(2), 299–316.
[30]
Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry, 2005: 57(11), 1215–1220.
[31]
Brookes K., Xu X., Chen W. et al.: The analysis of 51 genes in DSM-IV
combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol. Psychiatry, 2006: 11(10),
934–953.
[32]
Asherson P.: Attention-Deficit Hyperactivity Disorder in the post-genomic
era. Eur. Child Adolesc. Psychiatry, 2004: 13 Suppl. 1, I50–170.
[33]
Ogdie M.N., Fisher S.E., Yang M. et al.: Attention deficit hyperactivity disorder: fine mapping supports linkage to 5p13, 6q12, 16p13, and
17p11. Am. J. Hum. Genet., 2004: 75(4), 661–668.
[34]
Gothelf D., Michaelovsky E., Frisch A. et al.: Association of the lowactivity COMT 158Met allele with ADHD and OCD in subjects with
velocardiofacial syndrome. Int. J. Neuropsychopharmacol., 2007:10(3),
301–308.
[35]
Koth C.W., Cutting L.E., Denckla M.B.: The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Child Neuropsychol., 2000: 6(3), 185–194.
[36]
Curatolo P., Verdecchia M., Bombardieri R.: Tuberous sclerosis complex:
a review of neurological aspects. Eur. J. Paediatr. Neurol., 2002: 6(1),
15–23.
[37]
Baumgardner T., Reiss A., Freund L. et al.: Specification of the neurobehavioral phenotype in males with fragile X syndrome. Pediatrics, 1995:
95(5), 744–752.
[38]
Mick E., Biederman J., Faraone S.V. et al. Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use,
and drug use during pregnancy. J. Am. Acad. Child Adolesc. Psychiatry,
2002: 41(4), 378–385.
[39]
Hultman C.M., Torrang A., Tuvblad C. et al.: Birth weight and attentiondeficit/hyperactivity symptoms in childhood and early adolescence: a
prospective Swedish twin study. J. Am. Acad. Child Adolesc. Psychiatry, 2007: 46(3), 370–377.
[40]
McCann D., Barrett A., Cooper A. et al.: Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community:
a randomised, double-blinded, placebo-controlled trial. Lancet, 2007:
370(9598), 1560–1567.
[41]
Obel C., Linnet K.M., Henriksen T.B. et al.: Smoking during pregnancy
and hyperactivity-inattention in the offspring--comparing results from
three Nordic cohorts. Int. J. Epidemiol., 2008.
[42]
Coffin J.M., Baroody S., Schneider K. et al.: Impaired cerebellar learning in children with prenatal alcohol exposure: a comparative study of
eyeblink conditioning in children with ADHD and dyslexia. Cortex, 2005:
41(3), 389–398.
[43]
D’Onofrio B.M., Van Hulle C.A., Waldman I.D. et al.: Causal inferences
regarding prenatal alcohol exposure and childhood externalizing problems. Arch. Gen. Psychiatry, 2007: 64(11), 1296–1304.
[44]
Sen B., Swaminathan S.: Maternal prenatal substance use and behavior
problems among children in the U.S. J. Ment. Health. Policy Econ., 2007:
10(4), 189–206.
[45]
Milberger S., Biederman J., Faraone S.V., Chen L., Jones J.: Is maternal
smoking during pregnancy a risk factor for attention deficit hyperactivity
disorder in children? Am. J. Psychiatry, 1996: 153(9), 1138–1142.
[46]
Kotimaa A.J., Moilanen .I, Taanila A. et al. Maternal smoking and hyperactivity in 8-year-old children. J. Am. Acad. Child Adolesc. Psychiatry,
2003: 42(7), 826–33.
[47]
Potter A.S., Newhouse P.A., Bucci D.J.: Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity
disorder? Behav. Brain Res., 2006: 175(2), 201–211.
[48]
Weiss S., Tzavara E.T., Davis R.J. et al.: Functional alterations of nicotinic neurotransmission in dopamine transporter knock–out mice. Neuropharmacology, 2007: 52(7), 1496–1508.
[49]
Neuman R.J., Lobos E. Reich W. et al.: Prenatal smoking exposure and
dopaminergic genotypes interact to cause a severe ADHD subtype. Biol.
Psychiatry, 2007: 61(12), 1320–1328.
[50]
Becker K., El-Faddagh M., Schmidt M.H. et al.: Interaction of dopamine
transporter genotype with prenatal smoke exposure on ADHD symptoms. J. Pediatr., 2008:152(2), 263–269.
[51]
Spencer T.J., Biederman J., Madras B.K. et al.: In vivo neuroreceptor
imaging in attention–deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol. Psychiatry, 2005: 57(11), 1293–1300.
[52]
Valera E.M., Faraone S.V., Murray K.E. et al.: Meta–analysis of structural
imaging findings in attention–deficit/hyperactivity disorder. Biol. Psychiatry, 2007: 61(12), 1361–1369.
[53]
Castellanos F.X., Lee P.P., Sharp W. et al.: Developmental trajectories
of brain volume abnormalities in children and adolescents with attention–deficit/hyperactivity disorder. JAMA, 2002: 288(14), 1740–1748.
[54]
Shaw P.., Eckstrand K, Sharp W. et al.: Attention–deficit/hyperactivity
disorder is characterized by a delay in cortical maturation. Proc. Natl.
Acad. Sci. USA, 2007: 104(49), 19649–19654.
[55]
Mackie S., Shaw P., Lenroot R. et al.: Cerebellar development and clinical
outcome in attention deficit hyperactivity disorder. Am. J. Psychiatry,
2007: 164(4), 647–655.
[56]
Shaw P., Lerch J., Greenstein D. et al.: Longitudinal mapping of cortical
thickness and clinical outcome in children and adolescents with attention–deficit/hyperactivity disorder. Arch. Gen. Psychiatry, 2006: 63(5),
540–549.
[57]
Vaidya C.J., Austin G., Kirkorian G. et al.: Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc. Natl. Acad. Sci. USA, 1998:95(24), 14494–14499.
[58]
Zang Y.F., Jin Z., Weng X.C. et al.: Functional MRI in attention–deficit
hyperactivity disorder: evidence for hypofrontality. Brain Dev., 2005:
27(8), 544–550.
[59]
Vance A., Silk T.J., Casey M. et al.: Right parietal dysfunction in children
with attention deficit hyperactivity disorder, combined type: a functional
MRI study. Mol. Psychiatry, 2007: 12(9), 793, 826–832.
[60]
Shafritz K.M., Marchione K.E., Gore J.C. et al.: The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity
disorder. Am. J. Psychiatry, 2004: 161(11), 1990–1997.
[61]
Spencer T.J., Biederman J., Ciccone P.E. et al.: PET study examining
pharmacokinetics, detection and likeability, and dopamine transporter
receptor occupancy of short– and long–acting oral methylphenidate.
Am. J. Psychiatry, 2006: 163(3), 387–395.
[62]
Volkow N.D., Wang G.J., Fowler J.S. et al.: Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for
attention–deficit/hyperactivity disorder. Biol. Psychiatry, 2005: 57(11),
1410–1415.
[63]
Bush G., Spencer T.J., Holmes J. et al.: Functional magnetic resonance
imaging of methylphenidate and placebo in attention–deficit/hyperactivity disorder during the multi–source interference task. Arch. Gen. Psychiatry, 2008: 65(1), 102–114.
[64]
Pliszka S.R.: The neuropsychopharmacology of attention–deficit/hyperactivity disorder. Biol. Psychiatry, 2005: 57(11), 1385–1390.
[65]
Himelstein J., Newcorn J.H., Halperin J.M.: The neurobiology of attention–deficit hyperactivity disorder. Front. Biosci., 2000: 5, D461–478.
[66]
Biederman J., Spencer T.J.: Psychopharmacological interventions. Child
Adolesc Psychiatr. Clin. N. Am., 2008: 17(2), 439–58.
[67]
Levy F.: Pharmacological and therapeutic directions in ADHD: Specificity
in the PFC. Behav. Brain Funct., 2008: 4(1), 12.
[68]
Swanson J.M., Kraemer H.C., Hinshaw S.P. et al.: Clinical relevance of
the primary findings of the MTA: success rates based on severity of
ADHD and ODD symptoms at the end of treatment. J. Am. Acad. Child
Adolesc. Psychiatry, 2001: 40(2), 168–179.
[69]
Rapoport J.L., Gogtay N.: Brain neuroplasticity in healthy, hyperactive
and psychotic children: insights from neuroimaging. Neuropsychopharmacology, 2008: 33(1), 181–197.
[70]
Konrad K., Neufang S., Fink G.R. et al.: Long–term effects of methylphenidate on neural networks associated with executive attention in children with ADHD: results from a longitudinal functional MRI study. J. Am.
Acad. Child Adolesc. Psychiatry, 2007: 46(12), 1633–1641.
[71]
Coghill D.R., Rhodes S.M., Matthews K.: The neuropsychological effects
of chronic methylphenidate on drug–naive boys with attention–deficit/
hyperactivity disorder. Biol. Psychiatry, 2007: 62(9), 954–962.
[72]
Knobloch H., Pasamanick B.: Syndrome of minimal cerebral damage in
infancy. J. Am. Med. Assoc., 1959: 170(12), 1384–1387.
[73]
Clements S.: Minimal brain dysfunction in children: Terminology and
identification. Washington, DC: US Department of Health, Education and
Welfare 1966.
[74]
Durston S., Tottenham N.T., Thomas K.M. et al.: Differential patterns of
striatal activation in young children with and without ADHD. Biol. Psychiatry, 2003: 53(10), 871–878.
[75]
Allen A.J., Kurlan R.M., Gilbert D.L. et al.: Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology,
2005: 65(12), 1941–1949.
Scholar Google
PubMed